Spondyloarthritis & psoriatic arthritis
Impact of the digital health application ViViRA on spinal mobility, physical function, quality of life and pain perception in spondyloarthritides patients: a randomized controlled trial
Authors' conclusion
Our results highlight the efficacy of DHAs such as ViViRA in the treatment of lower back pain in SpAs patients. Compared with the current gold standard, physiotherapy, DHA use results in superior outcomes.
Study context
- Population
- SpA patients with chronic back pain59 analysed
- Comparison
- ViViRA digital health application vs standard physiotherapy
- Primary endpoint
- Pain (verbal rating scale, PAIN-Detect), quality of life (SF-36) and mobility (BASMI)
- Follow-up
- 12 weeks
Primary result
As reported in the abstract
Mobility (BASMI score, average), within-group change from baseline
| Group | Value | Baseline | Within-group P |
|---|---|---|---|
| Intervention | average 1.0 (range 0.5–1.4) | 1.1 [range 0.7-1.5] | p = 0.05 |
| Control | 1.8 (range 1.4–2.2) | 1.5 [range 1.1-1.9] | p = 0.00 |
Value
Interventionaverage 1.0 (range 0.5–1.4)
Control1.8 (range 1.4–2.2)
Baseline
Intervention1.1 [range 0.7-1.5]
Control1.5 [range 1.1-1.9]
Within-group P
Interventionp = 0.05
Controlp = 0.00
Further findings
| Outcome | Intervention | Control |
|---|---|---|
| Pain intensity (VRS pain level) · 12 weeksCo-primary outcome | 3.5 ± 2.8 | 4.5 ± 2 |
Pain intensity (VRS pain level) · 12 weeks
- Lower pain intensity with intervention than control
Original publication
Impact of the digital health application ViViRA on spinal mobility, physical function, quality of life and pain perception in spondyloarthritides patients: a randomized controlled trial. Arthritis Res Ther. Published 3 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →